Pembrolizumab plus lenvatinib for all advanced endometrial cancer? Maybe not
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Gynecological Cancer"
DOI: 10.1136/ijgc-2022-003419
Abstract: It was with great enthusiasm that I read the recently published KEYNOTE 775. Pembrolizumab plus lenvatinib showed unprecedented results for advanced, recurrent, or metastatic endometrial cancer with improvements in overall survival, progressionfree survival, response rates,… read more here.
Keywords: endometrial cancer; plus lenvatinib; pembrolizumab plus; response ... See more keywords